Featured Article

SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators

In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.

Guide

A Comprehensive Guide to Adaptive Site Monitoring

Download
Blog
QTLs: Where Are We, And How Much Further Can We Go?
  • Quality Tolerance Limits (QTLs) represent a significant advancement in clinical trial research, aimed at proactively identifying...
Read More
Blog
Risk-Based Quality Management (RBQM) Adoption: Shifting from “If” to “How” in Clinical Trials
  • Risk-Based Quality Management (RBQM) solutions allow Sponsors and CROs to confidently detect and effectively manage risk...
Read More
Blog
RACT Use in Clinical Trials: How to Implement Risk Assessment Categorization for Better Trial Outcomes
  • The move toward Risk-Based Quality Management (RBQM) is transforming the landscape of clinical trials by introducing...
Read More
Linkedin-in Facebook-f X-twitter Youtube
Who We Are
What We Do
Who We Work With
resources
Contact
© 2025 CluePoints. All Rights Reserved.
Privacy Policy
© 2025 CluePoints. All Rights Reserved. Privacy Policy